First Time Loading...

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 34.99 CNY 3.46% Market Closed
Updated: May 3, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Revenue
8.2B CNY
Cost of Revenue
-4.6B CNY
Gross Profit
3.6B CNY
Operating Expenses
-2.8B CNY
Operating Income
814.8m CNY
Other Expenses
171.9m CNY
Net Income
986.7m CNY

Margins Comparison
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
26.9B CNY
44%
10%
12%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
699.8B USD
79%
30%
15%
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK
85%
45%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
356.7B USD
70%
29%
50%
US
Merck & Co Inc
NYSE:MRK
322.3B USD
76%
11%
4%
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP
82%
19%
13%
CH
Novartis AG
SIX:NOVN
180.1B CHF
74%
27%
32%
CH
Roche Holding AG
SIX:ROG
172.6B CHF
73%
32%
20%
US
Pfizer Inc
NYSE:PFE
155.8B USD
70%
22%
4%
Country CN
Market Cap 26.9B CNY
Gross Margin
44%
Operating Margin
10%
Net Margin
12%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 699.8B USD
Gross Margin
79%
Operating Margin
30%
Net Margin
15%
Country DK
Market Cap 3.8T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
36%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 356.7B USD
Gross Margin
70%
Operating Margin
29%
Net Margin
50%
Country US
Market Cap 322.3B USD
Gross Margin
76%
Operating Margin
11%
Net Margin
4%
Country UK
Market Cap 186.4B GBP
Gross Margin
82%
Operating Margin
19%
Net Margin
13%
Country CH
Market Cap 180.1B CHF
Gross Margin
74%
Operating Margin
27%
Net Margin
32%
Country CH
Market Cap 172.6B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country US
Market Cap 155.8B USD
Gross Margin
70%
Operating Margin
22%
Net Margin
4%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
26.9B CNY
15%
10%
12%
10%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
699.8B USD
49%
9%
30%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK
88%
30%
79%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
356.7B USD
56%
23%
18%
14%
US
Merck & Co Inc
NYSE:MRK
322.3B USD
5%
2%
8%
4%
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP
16%
6%
13%
11%
CH
Novartis AG
SIX:NOVN
180.1B CHF
28%
14%
16%
14%
CH
Roche Holding AG
SIX:ROG
172.6B CHF
40%
13%
29%
22%
US
Pfizer Inc
NYSE:PFE
155.8B USD
2%
1%
8%
14%
Country CN
Market Cap 26.9B CNY
ROE
15%
ROA
10%
ROCE
12%
ROIC
10%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 699.8B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country DK
Market Cap 3.8T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 356.7B USD
ROE
56%
ROA
23%
ROCE
18%
ROIC
14%
Country US
Market Cap 322.3B USD
ROE
5%
ROA
2%
ROCE
8%
ROIC
4%
Country UK
Market Cap 186.4B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country CH
Market Cap 180.1B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%
Country CH
Market Cap 172.6B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country US
Market Cap 155.8B USD
ROE
2%
ROA
1%
ROCE
8%
ROIC
14%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More